LA
LGND icon

Linden Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Linden Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.67M Buy
+27,426
New +$6.46M 0.04% 230

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Linden Advisors's LGND Position: Q2 2026 in Review

Linden Advisors opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 27,426 shares worth $8.67M. The stake represents 0.04% of the portfolio and ranks #230 among its holdings.

414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Linden Advisors held 27,426 shares of Ligand Pharmaceuticals worth $8.67M as of Q2 2026.
  • Ligand Pharmaceuticals was a new Linden Advisors position in Q2 2026.
  • Ligand Pharmaceuticals made up 0.04% of Linden Advisors's portfolio in Q2 2026, its #230 holding.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Linden Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.